Dr David Montgomery begins his new role as Executive Director of Research at leading men’s health charity Prostate Cancer UK today. He replaces Dr Iain Frame, who left the charity in 2018 following his appointment as CEO at the National Cancer Research Institute.
Prostate cancer is the third biggest cancer killer in the UK and is the most commonly diagnosed cancer in men. Dr Montgomery will play a crucial role in driving forward research to help tackle some of the biggest issues facing the disease – from understanding more about who is at risk and getting closer to a screening programme, to improving treatments for advanced prostate cancer.
Dr Montgomery brings a wealth of experience to the charity. He initially trained as a surgeon, where he spent a period of time in breast cancer research before moving to the pharmaceutical industry in 2008, where his focus remained in oncology. He spent seven years as UK medical director at Pfizer, before being appointed Vice President of their Global Science Exchange group.
In addition to his role in Pfizer, David chaired the oncology medical directors’ forum at the Association of the British Pharmaceutical Industry (ABPI), sat as the industry representative on the national Cancer Drugs Fund (CDF) panel and as the industry representative on the National Cancer Research Initiative (NCRI) annual meeting scientific committee.
Dr Montgomery said:
“It’s a real honour to be appointed to such a fantastic charity. 1 in 8 men in the UK will get prostate cancer in their lifetime, and I’m excited to have the opportunity to use my experience both in medicine and the pharmaceutical industry to help make a real difference for these men.
“Prostate Cancer UK has an outstanding record when it comes to research and one of my key aims is to help drive the charity forward as it continues to take research from the lab, through trials and into clinics as soon as possible.”
Dr Montgomery will work closely with Chief Executive Angela Culhane and the Board to help Prostate Cancer UK launch the next phase of its ambitious research programme, bringing the charity closer to its overall goal of stopping prostate cancer being a killer.
Angela Culhane said:
“We are very pleased to welcome David on to the Executive Team here at Prostate Cancer UK and I look forward to working with him to tackle some of the biggest issues facing prostate cancer.
“Over recent years we have seen unprecedented growth in our research portfolio, with investment to date now totalling over £50 million. David’s experience, broad strategic insight and industry knowledge will be a huge asset as he takes us forward into the next phase, which will see us continue to increase our research spend and implement increasingly exciting programmes. I look forward to working closely with David to achieve the biggest possible impact from research for men facing prostate cancer.”